首页|基于MAPK信号通路探讨中医药治疗肝癌的研究进展

基于MAPK信号通路探讨中医药治疗肝癌的研究进展

扫码查看
肝癌是全球常见的恶性肿瘤之一.丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)信号通路是生物体内重要的信号转导系统之一,具有调节细胞的生长、分化、凋亡等多种功能,与肝癌细胞的增殖、凋亡、侵袭转移、自噬等细胞活动密切相关.中医药通过干预MAPK通路下游蛋白来调节细胞周期蛋白表达,阻滞细胞通过G1期进入S期,从而抑制增殖;通过上调促凋亡蛋白与下调抑凋亡蛋白,激活半胱氨酸蛋白水解酶(Caspase)级联反应促进细胞凋亡;通过下调基质金属蛋白酶(matrix metalloproteinase,MMP)、血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达,抑制上皮—间质转化(epithelial-mesenchymal transition,EMT),从而降低肝癌细胞侵袭转移能力;上调自噬相关蛋白的表达,促进肝癌细胞自噬.本文通过检索近年来相关文献,就中医药基于MAPK通路治疗肝癌的机制进行综述.
Research progress of liver cancer intervened by TCM based on MAPK signaling pathway
Liver tumor is one of the most common malignant tumors worldwide.The mitogen-activated protein kinase(MAPK)signaling pathway has various functions such as regulating cell growth,differentiation,and apoptosis,and is closely related to cell activities such as proliferation,apoptosis,invasion and metastasis,and autophagy of hepatoma cells.Traditional Chinese medicine regulates cell cycle protein expression by intervening in downstream proteins of the MAPK pathway,and blocks cells from entering the S phase through the G1 phase,thereby inhibiting proliferation.By up-regulating apoptotic protein and down-regulating apoptotic protein,the cysteine proteolytic enzyme(Caspase)cascade reaction is activated to promote apoptosis;by downregulating the expression of matrix metalloproteinase(MMP)and vascular endothelial growth factor(VEGF),epithelial-mesenchymal transition(EMT)is inhibited,thereby reducing the invasion and metastasis ability of hepatoma cells;by upregulating the expression of au-tophagy-related proteins to promote autophagy in hepatoma cells.This paper reviews the mechanism of traditional Chinese medicine in the treatment of liver cancer based on the MAPK pathway by searching relevant literature in recent years..

liver cancertraditional Chinese medicineMAPKproliferationapoptosisinvasion and metastasisautophagy

张格松、蒋士卿

展开 >

450046 郑州,河南中医药大学第一临床医学院

河南中医药大学第一附属医院血液肿瘤科

肝癌 中医药 丝裂原活化蛋白激酶 增殖 凋亡 侵袭转移 自噬

河南省中医药科学研究专项河南省卫生健康委国家中医临床研究基地科研专项

2019ZYZD062022JDZX083

2024

环球中医药
中华国际医学交流基金会

环球中医药

CSTPCD
影响因子:1.553
ISSN:1674-1749
年,卷(期):2024.17(4)
  • 46